• shareshare
  • link
  • cite
  • add
auto_awesome_motion View all 6 versions
Publication . Preprint . 2021

Short and medium-term challenges for COVID-19 vaccination: from prioritisation to the relaxation of measures

Tran Kiem, Cécile; Massonnaud, Clément; Levy-Bruhl, Daniel; Poletto, Chiara; Colizza, Vittoria; Bosetti, Paolo; Fontanet, Arnaud; +6 Authors
Published: 06 Apr 2021
Publisher: HAL CCSD
Country: France
BackgroundThe roll-out of COVID-19 vaccines is a multi-faceted challenge whose performance depends on pace of vaccination, vaccine characteristics and heterogeneities in individual risks.MethodsWe developed a mathematical model accounting for the risk of severe disease by age and comorbidity and transmission dynamics. We compared vaccine prioritisation strategies in the early roll-out stage and quantified the extent to which measures could be relaxed as a function of the vaccine coverage achieved in France.FindingsPrioritizing at-risk individuals reduces morbi-mortality the most if vaccines only reduce severity, but is of less importance if vaccines also substantially reduce infectivity or susceptibility. Age is the most important factor to consider for prioritization; additionally accounting for comorbidities increases the performance of the campaign in a context of scarce resources. Vaccinating 90% of ≥65 y.o. and 70% of 18-64 y.o. before the autumn 2021 with a vaccine that reduces severity by 90% and susceptibility by 80%, we find that control measures reducing transmission rates by 15-27% should be maintained to remain below 1,000 daily hospital admissions in France with a highly transmissible variant (basic reproduction numberR0=4). Assuming 90% of ≥65 y.o. are vaccinated, full relaxation of control measures might be achieved with a vaccine coverage of 89-100% in 18-64 y.o or 60-69% of 0-64 y.o.InterpretationEven in optimistic scenarios, current vaccination intentions in the French populations might not allow a complete relaxation of control measures. Vaccination of children, if possible, could help achieve this objective.

[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, COVID-19, Vaccination

27 Béraud G, Kazmercziak S, Beutels P, et al. The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases. PLoS One 2015; 10: e0133203. [OpenAIRE]

28 Carrat F, de Lamballerie X, Rahib D, et al. Seroprevalence of SARS-CoV-2 Among Adults in Three Regions of France Following the Lockdown and Associated Risk Factors: A Multicohort Study. SSRN Electronic Journal. 2020. DOI:10.2139/ssrn.3696820.

29 Lapidus N, Paireau J, Levy-Bruhl D, et al. Ready for a BASE jump? Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. 2020. DOI:10.1101/2020.11.06.20227025.

30 Hozé N, Paireau J, Lapidus N, et al. Monitoring the proportion infected by SARS-CoV-2 from age-stratified hospitalisation and serological data. medRxiv 2021; : 2021.01.11.21249435.

31 Lefrancq N, Paireau J, Hozé N, et al. Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis. The Lancet Regional Health - Europe 2021; 5: 100087. [OpenAIRE]

33 Kim L, Garg S, O'Halloran A, et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVIDNET). Clin Infect Dis 2020; published online July 16. DOI:10.1093/cid/ciaa1012.

34 Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020; 368: 489-93.

35 Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature 2020; 584: 425-9.

36 Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol 1990; 28: 365-82. [OpenAIRE]

37 Kim Y-J, Oremus M, Chen HH, McFarlane T, Fearon D, Horton S. Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. J Comp Eff Res 2021; published online Feb 5. DOI:10.2217/cer-2020-0173.

Funded by
Versatile Emerging infectious disease Observatory
  • Funder: European Commission (EC)
  • Project Code: 874735
  • Funding stream: H2020 | RIA
Related to Research communities